{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Secukinumab+Injection", "query": { "intervention": "Secukinumab Injection" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 54, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Secukinumab+Injection&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-09T01:15:20.349Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02594098", "title": "Secukinumab for Treatment of Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Secukinumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2015-11", "completion_date": "2018-01-30", "has_results": true, "last_update_posted_date": "2019-06-12", "last_synced_at": "2026-09-09T01:15:20.349Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02594098" }, { "nct_id": "NCT01828086", "title": "Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Plaque-type Psoriasis" ], "interventions": [ { "name": "CJM112", "type": "BIOLOGICAL" }, { "name": "Secukinumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 95, "start_date": "2013-06", "completion_date": "2015-10", "has_results": false, "last_update_posted_date": "2020-12-11", "last_synced_at": "2026-09-09T01:15:20.349Z", "location_count": 18, "location_summary": "Anniston, Alabama • Anaheim, California • Encino, California + 14 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "North Hollywood", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01828086" }, { "nct_id": "NCT02159053", "title": "16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Spondylitis, Ankylosing" ], "interventions": [ { "name": "Secukinumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 350, "start_date": "2015-05-18", "completion_date": "2018-01-02", "has_results": true, "last_update_posted_date": "2019-04-10", "last_synced_at": "2026-09-09T01:15:20.349Z", "location_count": 12, "location_summary": "Anniston, Alabama • Upland, California • Aventura, Florida + 9 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Upland", "state": "California" }, { "city": "Aventura", "state": "Florida" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Shreveport", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02159053" }, { "nct_id": "NCT05080218", "title": "COVID-19 VaccinE Response in Rheumatology Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis", "Psoriatic Arthritis", "Spondylarthritis" ], "interventions": [ { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Abatacept", "type": "DRUG" }, { "name": "Secukinumab", "type": "DRUG" }, { "name": "Tofacitinib", "type": "DRUG" }, { "name": "TNF Inhibitor", "type": "DRUG" }, { "name": "Canakinumab Injection", "type": "DRUG" }, { "name": "Baricitinib", "type": "DRUG" }, { "name": "Ixekizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jeffrey Curtis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 841, "start_date": "2021-11-15", "completion_date": "2024-05-28", "has_results": false, "last_update_posted_date": "2025-05-02", "last_synced_at": "2026-09-09T01:15:20.349Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Hoover", "state": "Alabama" }, { "city": "Hoover", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05080218" }, { "nct_id": "NCT01358175", "title": "16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ankylosing Spondylitis" ], "interventions": [ { "name": "Secukinumab (75 mg)", "type": "DRUG" }, { "name": "Secukinumab (150 mg)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 371, "start_date": "2011-10", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2017-03-09", "last_synced_at": "2026-09-09T01:15:20.349Z", "location_count": 10, "location_summary": "Boise, Idaho • Cedar Rapids, Iowa • Portland, Oregon + 7 more", "locations": [ { "city": "Boise", "state": "Idaho" }, { "city": "Cedar Rapids", "state": "Iowa" }, { "city": "Portland", "state": "Oregon" }, { "city": "Duncansville", "state": "Pennsylvania" }, { "city": "Jackson", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01358175" }, { "nct_id": "NCT02798211", "title": "Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Psoriatic Arthritis" ], "interventions": [ { "name": "Secukinumab 300 mg", "type": "DRUG" }, { "name": "Secukinumab 150 mg", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 258, "start_date": "2016-06-27", "completion_date": "2018-12-05", "has_results": true, "last_update_posted_date": "2021-10-07", "last_synced_at": "2026-09-09T01:15:20.349Z", "location_count": 57, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • El Cajon, California + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "El Cajon", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02798211" }, { "nct_id": "NCT02294227", "title": "16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis, Psoriatic" ], "interventions": [ { "name": "Secukinumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 341, "start_date": "2015-05-29", "completion_date": "2017-12-19", "has_results": true, "last_update_posted_date": "2019-07-02", "last_synced_at": "2026-09-09T01:15:20.349Z", "location_count": 19, "location_summary": "Mesa, Arizona • Upland, California • Denver, Colorado + 15 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Upland", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Palm Harbor", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02294227" }, { "nct_id": "NCT02471144", "title": "Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Severe Plaque-type Psoriasis" ], "interventions": [ { "name": "Experimental : Secukinumab low dose", "type": "BIOLOGICAL" }, { "name": "Experimental: Secukinumab high dose", "type": "BIOLOGICAL" }, { "name": "Placebo Comparator: Secukinumab Placebo", "type": "BIOLOGICAL" }, { "name": "Active Comparator: Etanercept", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 162, "start_date": "2015-09-29", "completion_date": "2023-03-30", "has_results": true, "last_update_posted_date": "2023-10-11", "last_synced_at": "2026-09-09T01:15:20.349Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02471144" }, { "nct_id": "NCT05320159", "title": "Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Secukinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 17743, "start_date": "2021-02-03", "completion_date": "2021-03-31", "has_results": false, "last_update_posted_date": "2022-07-01", "last_synced_at": "2026-09-09T01:15:20.349Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05320159" }, { "nct_id": "NCT01640951", "title": "4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Moderate to Severe Chronic Plaque-Type Psoriasis" ], "interventions": [ { "name": "AIN457 150 mg", "type": "DRUG" }, { "name": "AIN457 300 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 675, "start_date": "2012-09-16", "completion_date": "2017-05-04", "has_results": true, "last_update_posted_date": "2018-05-25", "last_synced_at": "2026-09-09T01:15:20.349Z", "location_count": 28, "location_summary": "Fresno, California • Pasadena, California • San Francisco, California + 24 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01640951" } ] }